Skip to main content
Top
Published in: Acta Diabetologica 6/2013

01-12-2013 | Original Article

Adiponectin increases glucose-induced insulin secretion through the activation of lipid oxidation

Authors: G. Patané, N. Caporarello, P. Marchetti, C. Parrino, D. Sudano, L. Marselli, R. Vigneri, L. Frittitta

Published in: Acta Diabetologica | Issue 6/2013

Login to get access

Abstract

The expression of adiponectin receptors has been demonstrated in human and rat pancreatic beta cells, where globular (g) adiponectin rescues rat beta cells from cytokine and fatty acid-induced apoptosis. The aim of our study was to evaluate whether adiponectin has a direct effect on insulin secretion and the metabolic pathways involved. Purified human pancreatic islets and rat beta cells (INS-1E) were exposed (1 h) to g-adiponectin, and glucose-induced insulin secretion was measured. A significant increase in glucose-induced insulin secretion was observed in the presence of g-adiponectin (1 nmol/l) with respect to control cells in both human pancreatic islets (n = 5, p < 0.05) and INS-1E cells (n = 5, p < 0.001). The effect of globular adiponectin on insulin secretion was independent of AMP-dependent protein kinase (AMPK) activation or glucose oxidation. In contrast, g-adiponectin significantly increased oleate oxidation (n = 5, p < 0.05), and the effect of g-adiponectin (p < 0.001) on insulin secretion by INS-1E was significantly reduced in the presence of etomoxir (1 μmol/l), an inhibitor of fatty acid beta oxidation. g-Adiponectin potentiates glucose-induced insulin secretion in both human pancreatic islets and rat beta cells via an AMPK independent pathway. Increased fatty acid oxidation rather than augmented glucose oxidation is the mechanism responsible. Overall, our data indicate that, in addition to its anti-apoptotic action, g-adiponectin has another direct effect on beta cells by potentiating insulin secretion. Adiponectin, therefore, in addition to its well-known effect on insulin sensitivity, has important effects at the pancreatic level.
Literature
1.
2.
go back to reference King GA, Deemer SE, Thompson DL (2012) Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta Diabetol 49(suppl 1):41–49CrossRef King GA, Deemer SE, Thompson DL (2012) Adiponectin is associated with risk of the metabolic syndrome and insulin resistance in women. Acta Diabetol 49(suppl 1):41–49CrossRef
3.
go back to reference Baratta R, Amato S, Degano C et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89(6):2665–2671PubMedCrossRef Baratta R, Amato S, Degano C et al (2004) Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. J Clin Endocrinol Metab 89(6):2665–2671PubMedCrossRef
4.
go back to reference Su SC, Pei D, Hsieh CH et al (2011) Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol 48(2):113–119PubMedCrossRef Su SC, Pei D, Hsieh CH et al (2011) Circulating pro-inflammatory cytokines and adiponectin in young men with type 2 diabetes. Acta Diabetol 48(2):113–119PubMedCrossRef
5.
go back to reference Kishida K, Funahashi T, Shimomura I (2012) Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets 12(2):118–131PubMedCrossRef Kishida K, Funahashi T, Shimomura I (2012) Molecular mechanisms of diabetes and atherosclerosis: role of adiponectin. Endocr Metab Immune Disord Drug Targets 12(2):118–131PubMedCrossRef
6.
go back to reference Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef Yamauchi T, Kamon J, Ito Y et al (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769PubMedCrossRef
7.
go back to reference Tomas E, Tsao TS, Saha AK et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313PubMedCrossRef Tomas E, Tsao TS, Saha AK et al (2002) Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99:16309–16313PubMedCrossRef
8.
go back to reference Kharroubi I, Rasschaert J, Eizirik DL, Cnop M (2003) Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun 312:1118–1122PubMedCrossRef Kharroubi I, Rasschaert J, Eizirik DL, Cnop M (2003) Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun 312:1118–1122PubMedCrossRef
9.
go back to reference Musso G, Gambino R, Biroli G et al (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100(11):2438–2446PubMedCrossRef Musso G, Gambino R, Biroli G et al (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100(11):2438–2446PubMedCrossRef
10.
go back to reference Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258PubMedCrossRef Rakatzi I, Mueller H, Ritzeler O, Tennagels N, Eckel J (2004) Adiponectin counteracts cytokine- and fatty acid-induced apoptosis in the pancreatic beta-cell line INS-1. Diabetologia 47:249–258PubMedCrossRef
11.
go back to reference Beylot M, Pinteur C, Peroni O (2006) Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 55:396–401PubMedCrossRef Beylot M, Pinteur C, Peroni O (2006) Expression of the adiponectin receptors AdipoR1 and AdipoR2 in lean rats and in obese Zucker rats. Metabolism 55:396–401PubMedCrossRef
12.
go back to reference Staiger K, Stefan N, Staiger H et al (2005) Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 90(12):6707–6713PubMedCrossRef Staiger K, Stefan N, Staiger H et al (2005) Adiponectin is functionally active in human islets but does not affect insulin secretory function or beta-cell lipoapoptosis. J Clin Endocrinol Metab 90(12):6707–6713PubMedCrossRef
13.
go back to reference Wijesekara N, Krishnamurthy M, Bhattacharjee A et al (2010) Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 285(44):33623–33631PubMedCrossRef Wijesekara N, Krishnamurthy M, Bhattacharjee A et al (2010) Adiponectin-induced ERK and Akt phosphorylation protects against pancreatic beta cell apoptosis and increases insulin gene expression and secretion. J Biol Chem 285(44):33623–33631PubMedCrossRef
14.
go back to reference Gu W, Li X, Liu C et al (2006) Globular adiponectin augments insulin secretion from pancreatic islet beta cells at high glucose concentrations. Endocrine 30:217–221PubMedCrossRef Gu W, Li X, Liu C et al (2006) Globular adiponectin augments insulin secretion from pancreatic islet beta cells at high glucose concentrations. Endocrine 30:217–221PubMedCrossRef
15.
go back to reference Okamoto M, Ohara-Imaizumi M, Kubota N et al (2008) Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827–835PubMedCrossRef Okamoto M, Ohara-Imaizumi M, Kubota N et al (2008) Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827–835PubMedCrossRef
16.
go back to reference Winzell MS, Nogueiras R, Dieguez C, Ahren B (2004) Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154–160PubMedCrossRef Winzell MS, Nogueiras R, Dieguez C, Ahren B (2004) Dual action of adiponectin on insulin secretion in insulin-resistant mice. Biochem Biophys Res Commun 321:154–160PubMedCrossRef
17.
go back to reference Lupi R, Dotta F, Marselli L et al (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51:1437–1442PubMedCrossRef Lupi R, Dotta F, Marselli L et al (2002) Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 51:1437–1442PubMedCrossRef
18.
go back to reference Di Paola R, Caporarello N, Marucci A et al (2011) ENPP1 affects insulin action and secretion: evidences from in vitro studies. PLoS ONE 6(5):e19462PubMedCrossRef Di Paola R, Caporarello N, Marucci A et al (2011) ENPP1 affects insulin action and secretion: evidences from in vitro studies. PLoS ONE 6(5):e19462PubMedCrossRef
19.
go back to reference Andersson U, Filipsson K, Abbott CR et al (2004) AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279:12005–12008PubMedCrossRef Andersson U, Filipsson K, Abbott CR et al (2004) AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 279:12005–12008PubMedCrossRef
20.
go back to reference Patane G, Anello M, Piro S et al (2002) Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. Diabetes 51:2749–2756PubMedCrossRef Patane G, Anello M, Piro S et al (2002) Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor-gamma inhibition. Diabetes 51:2749–2756PubMedCrossRef
21.
go back to reference Patane G, Piro S, Rabuazzo AM et al (2000) Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 49:735–740PubMedCrossRef Patane G, Piro S, Rabuazzo AM et al (2000) Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 49:735–740PubMedCrossRef
22.
go back to reference Marchetti P, Dotta F, Lauro D et al (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept 146(1–3):4–11PubMedCrossRef Marchetti P, Dotta F, Lauro D et al (2008) An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept 146(1–3):4–11PubMedCrossRef
23.
go back to reference Fischer S, Santos AN, Thieme R et al (2010) Adiponectin stimulates glucose uptake in rabbit blastocysts. Biol Reprod 83(5):859–865PubMedCrossRef Fischer S, Santos AN, Thieme R et al (2010) Adiponectin stimulates glucose uptake in rabbit blastocysts. Biol Reprod 83(5):859–865PubMedCrossRef
24.
go back to reference Iwabu M, Yamauchi T, Okada-Iwabu M et al (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2 +) and AMPK/SIRT1. Nature 464(7293):1313–1319PubMedCrossRef Iwabu M, Yamauchi T, Okada-Iwabu M et al (2010) Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2 +) and AMPK/SIRT1. Nature 464(7293):1313–1319PubMedCrossRef
25.
go back to reference Huypens P, Moens K, Heimberg H et al (2005) Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 77(11):1273–1282PubMedCrossRef Huypens P, Moens K, Heimberg H et al (2005) Adiponectin-mediated stimulation of AMP-activated protein kinase (AMPK) in pancreatic beta cells. Life Sci 77(11):1273–1282PubMedCrossRef
26.
go back to reference Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef Berg AH, Combs TP, Du X, Brownlee M, Scherer PE (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947–953PubMedCrossRef
27.
go back to reference Kadowaki T, Yamauchi T, Kubota N et al (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792PubMedCrossRef Kadowaki T, Yamauchi T, Kubota N et al (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116:1784–1792PubMedCrossRef
28.
go back to reference Kantartzis K, Rittig K, Balletshofer B et al (2006) The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 52:1934–1942PubMedCrossRef Kantartzis K, Rittig K, Balletshofer B et al (2006) The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 52:1934–1942PubMedCrossRef
Metadata
Title
Adiponectin increases glucose-induced insulin secretion through the activation of lipid oxidation
Authors
G. Patané
N. Caporarello
P. Marchetti
C. Parrino
D. Sudano
L. Marselli
R. Vigneri
L. Frittitta
Publication date
01-12-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 6/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-013-0458-x

Other articles of this Issue 6/2013

Acta Diabetologica 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.